• AgoraVox sur Twitter
  • RSS
  • Agoravox TV
  • Agoravox Mobile


Commentaire de njama

sur NON, vraiment rien ne justifie de recommander le vaccin Gardasil contre HPV


Voir l'intégralité des commentaires de cet article

njama njama 31 mai 2019 17:24

pour enfoncer un peu plus le clou
Page 10
« Historically, HPV testing [15] was introduced to compensate for the poor sensitivity and specificity of the Pap smear cytology often used as a diagnostic tool for borderline precancerouslesions. The only FDA approved Digene Hybrid Capture 2 (HC2) assay is commonly used to determine if a cervicovaginal lavage sample harbors »high-risk« HPVs [16], as an adjunctive test for evaluation of the cytologically borderline cases [17-19]. However, it is now recognized that persistent infection of a »high-risk« HPV, not the HPV virus itself, is the pivotal promoter incausing cervical precancerous lesions and cancer [7-10].
Most of HPV infections, even caused by »high-risk« genotypes, are transient with normal Pap cytology in sexually active young women [1, 3-6]. In 93% of the initially infected women, the same viral type is not detected upon re-examination four menstrual cycles later [20]. The median duration of positivity detectable by PCR for a specific HPV type in these young women is 168 days [21]. Multiple »high-risk« HPV infections do not constitute a higher risk for the development of cervical neoplasia when compared with single high-risk HPV infection [22]. For the development and maintenance of a high-grade squamous intra epithelial lesion (SIL), the risk is greatest in women positive for the same genotype of HPV on repeated testing [7-9]. Viral load is not a useful parameter to predict high-grade SIL [23]. High-grade SIL is often associated with a viral DNA load lower than that observed in less severely affected cells [24] »

Répondre Signaler un abus

Voir ce commentaire dans son contexte


Derniers commentaires




Palmarès